IMR Press / FBL / Volume 11 / Issue 1 / DOI: 10.2741/1826

Frontiers in Bioscience-Landmark (FBL) is published by IMR Press from Volume 26 Issue 5 (2021). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on as a courtesy and upon agreement with Frontiers in Bioscience.

Open Access Article

Molecular Pathogenesis of Hepatolithiasis — A Type of Low Phospholipid-Associated Cholelithiasis

Show Less
1 Department of Gastroenterology, Institute of Clinical Medicine, The University of Tsukuba, 1-1-1 Tennodai, Tsukuba-shi, Ibaraki 305-8575, Japan
2 Pharmacology Research, R&D, Kissei Pharmaceutical Co., Ltd., 4365-1 Kashiwabara, Hotaka, Azumino-shi, Nagano 399-8304, Japan
3 Aikawa Hospital, Daihata, Senba, Mito-shi, Ibaraki 305-8575, Japan
Academic Editor:Mohammad Abedin
Front. Biosci. (Landmark Ed) 2006, 11(1), 669–675;
Published: 1 January 2006
(This article belongs to the Special Issue Molecular basis of gallstone pathogenesis)

Hepatolithiasis is prevalent in East Asia, including Japan, but occurs much less frequently in Western countries. Hepatolithiasis appears mostly as brown pigment stones (calcium bilirubinate stones). The disease is characterized by its intractable nature and frequent recurrence, requiring multiple endoscopic or operative interventions, in distinct contrast to gallbladder cholesterol or black pigment stones. In view of the lack of information on the pathogenesis, a multidisciplinary approach has been carried out through the Hepatolithiasis Research Group organized by the Ministry of Health, Labor and Welfare of Japan. In this review, the up-to-date data on the molecular pathogenesis of hepatolithiasis with special reference to a defect in phospholipid metabolism are introduced and discussed. Furthermore, a potential medical treatment targeting hepatic phospholipid transporters is proposed as a future therapeutic option for the disease.

Back to top